fasudil has been researched along with Apoplexy in 14 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A multicenter, double-blind, placebo-controlled study was conducted to assess the efficacy and safety of fasudil, a Rho-kinase inhibitor (RKI), in the treatment of acute ischemic stroke." | 9.11 | Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial. ( Hirai, S; Ohtomo, E; Satoh, S; Seto, M; Shibuya, M, 2005) |
| "Four groups of rats were randomized as follows: Cerebral ischemia-reperfusion (IR), Fasudil, CIMT and CIMT + Fasudil." | 8.12 | Combination of constraint-induced movement therapy with fasudil amplifies neurogenesis after focal cerebral ischemia/reperfusion in rats. ( Guo, Y; Zhai, Z, 2022) |
| "Early CIMT promotes motor recovery after acute ischemic stroke when it is administered with fasudil pharmacotherapy, but not without it." | 7.83 | Combination of early constraint-induced movement therapy and fasudil enhances motor recovery after ischemic stroke in rats. ( Bonney, E; Chen, YH; Huang, FZ; Liu, BQ; Liu, YH; Wang, HX; Zhao, Y, 2016) |
| "Fasudil, a Rho-kinase inhibitor, is a promising neuroprotectant against ischemic stroke; however, its low bioavailability is an obstacle to be overcome." | 7.83 | Neuroprotection against cerebral ischemia/reperfusion injury by intravenous administration of liposomal fasudil. ( Asai, T; Fukuta, T; Kikuchi, T; Koide, H; Namba, M; Oku, N; Sato, A; Shimizu, K; Yanagida, Y, 2016) |
| " To determine if a ROCK mechanism is involved in simvastatin-induced neuroprotection following embolic strokes, we used pharmacological intervention with the ROCK inhibitor, fasudil." | 7.76 | Simvastatin improves clinical scores in a rabbit multiple infarct ischemic stroke model: synergism with a ROCK inhibitor but not the thrombolytic tissue plasminogen activator. ( Han, MK; Lapchak, PA, 2010) |
| "These results suggest that fasudil has beneficial effects on retinal vascular complications associated with chronic hypertension." | 7.74 | Vasodilator effects of fasudil, a Rho-kinase inhibitor, on retinal arterioles in stroke-prone spontaneously hypertensive rats. ( Ishii, K; Kametaka, S; Mori, A; Nakahara, T; Okamura, N; Saito, M; Sakamoto, K, 2007) |
| "A multicenter, double-blind, placebo-controlled study was conducted to assess the efficacy and safety of fasudil, a Rho-kinase inhibitor (RKI), in the treatment of acute ischemic stroke." | 5.11 | Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial. ( Hirai, S; Ohtomo, E; Satoh, S; Seto, M; Shibuya, M, 2005) |
| "Four groups of rats were randomized as follows: Cerebral ischemia-reperfusion (IR), Fasudil, CIMT and CIMT + Fasudil." | 4.12 | Combination of constraint-induced movement therapy with fasudil amplifies neurogenesis after focal cerebral ischemia/reperfusion in rats. ( Guo, Y; Zhai, Z, 2022) |
| "Early CIMT promotes motor recovery after acute ischemic stroke when it is administered with fasudil pharmacotherapy, but not without it." | 3.83 | Combination of early constraint-induced movement therapy and fasudil enhances motor recovery after ischemic stroke in rats. ( Bonney, E; Chen, YH; Huang, FZ; Liu, BQ; Liu, YH; Wang, HX; Zhao, Y, 2016) |
| "Fasudil, a Rho-kinase inhibitor, is a promising neuroprotectant against ischemic stroke; however, its low bioavailability is an obstacle to be overcome." | 3.83 | Neuroprotection against cerebral ischemia/reperfusion injury by intravenous administration of liposomal fasudil. ( Asai, T; Fukuta, T; Kikuchi, T; Koide, H; Namba, M; Oku, N; Sato, A; Shimizu, K; Yanagida, Y, 2016) |
| "We investigated the neuroprotective effects of fasudil's active metabolite, hydroxyfasudil, a Rho-kinase inhibitor, in a rat stroke model in which endothelial damage and subsequent thrombotic occlusion were selectively induced in perforating arteries." | 3.76 | Amelioration of endothelial damage/dysfunction is a possible mechanism for the neuroprotective effects of Rho-kinase inhibitors against ischemic brain damage. ( Asano, T; Hitomi, A; Ikegaki, I; Iwasaki, M; Kawasaki, K; Mohri, M; Nakazono, O; Satoh, S, 2010) |
| " To determine if a ROCK mechanism is involved in simvastatin-induced neuroprotection following embolic strokes, we used pharmacological intervention with the ROCK inhibitor, fasudil." | 3.76 | Simvastatin improves clinical scores in a rabbit multiple infarct ischemic stroke model: synergism with a ROCK inhibitor but not the thrombolytic tissue plasminogen activator. ( Han, MK; Lapchak, PA, 2010) |
| "These results suggest that fasudil has beneficial effects on retinal vascular complications associated with chronic hypertension." | 3.74 | Vasodilator effects of fasudil, a Rho-kinase inhibitor, on retinal arterioles in stroke-prone spontaneously hypertensive rats. ( Ishii, K; Kametaka, S; Mori, A; Nakahara, T; Okamura, N; Saito, M; Sakamoto, K, 2007) |
| "Ischemic stroke is a deleterious cerebrovascular disease with few therapeutic options, and its functional recovery is highly associated with the integrity of the blood-brain barrier and neuroinflammation." | 1.91 | FDCA Attenuates Neuroinflammation and Brain Injury after Cerebral Ischemic Stroke. ( Guan, X; Huang, Z; Liang, Z; Pang, T; Wang, Y; Wei, D; Wu, J; Xie, L, 2023) |
| "Hyperlipidemia is a major cardiovascular risk factor associated with progressive cerebrovascular dysfunction and diminished collateral perfusion in stroke." | 1.40 | Rho-kinase inhibition improves ischemic perfusion deficit in hyperlipidemic mice. ( Ayata, C; Huang, PL; Shin, HK, 2014) |
| "Treatment with fasudil (1 and 10 mg/kg, n=15 each) resulted in a significant improvement in neurological deficits." | 1.31 | A new model of cerebral microthrombosis in rats and the neuroprotective effect of a Rho-kinase inhibitor. ( Asano, T; Ikegaki, I; Satoh, S; Toshima, Y, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (35.71) | 29.6817 |
| 2010's | 7 (50.00) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Guan, X | 1 |
| Wei, D | 1 |
| Liang, Z | 1 |
| Xie, L | 1 |
| Wang, Y | 1 |
| Huang, Z | 2 |
| Wu, J | 1 |
| Pang, T | 1 |
| Zhai, Z | 1 |
| Guo, Y | 1 |
| Chan, SL | 1 |
| Cipolla, MJ | 1 |
| Shin, HK | 1 |
| Huang, PL | 1 |
| Ayata, C | 1 |
| Liu, YH | 1 |
| Zhao, Y | 1 |
| Huang, FZ | 1 |
| Chen, YH | 1 |
| Wang, HX | 1 |
| Bonney, E | 1 |
| Liu, BQ | 1 |
| Fukuta, T | 1 |
| Asai, T | 1 |
| Sato, A | 1 |
| Namba, M | 1 |
| Yanagida, Y | 1 |
| Kikuchi, T | 1 |
| Koide, H | 1 |
| Shimizu, K | 1 |
| Oku, N | 1 |
| Feske, SK | 1 |
| Sorond, FA | 1 |
| Henderson, GV | 1 |
| Seto, M | 3 |
| Hitomi, A | 2 |
| Kawasaki, K | 3 |
| Sasaki, Y | 1 |
| Asano, T | 4 |
| Liao, JK | 2 |
| Satoh, S | 3 |
| Ikegaki, I | 3 |
| Nakazono, O | 1 |
| Iwasaki, M | 1 |
| Mohri, M | 1 |
| Lapchak, PA | 1 |
| Han, MK | 1 |
| Ishiguro, M | 1 |
| Suzuki, Y | 1 |
| Ishizuka, F | 1 |
| Mishiro, K | 1 |
| Egashira, Y | 1 |
| Tsuruma, K | 1 |
| Shimazawa, M | 1 |
| Yoshimura, S | 1 |
| Iwama, T | 1 |
| Hara, H | 1 |
| Shibuya, M | 1 |
| Hirai, S | 1 |
| Ohtomo, E | 1 |
| Rikitake, Y | 1 |
| Kim, HH | 1 |
| Yano, K | 1 |
| Moskowitz, MA | 1 |
| Okamura, N | 1 |
| Saito, M | 1 |
| Mori, A | 1 |
| Sakamoto, K | 1 |
| Kametaka, S | 1 |
| Nakahara, T | 1 |
| Ishii, K | 1 |
| Toshima, Y | 1 |
1 trial available for fasudil and Apoplexy
| Article | Year |
|---|---|
Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acute Disease; Aged; Brain Ischemia; Dose-Response Re | 2005 |
13 other studies available for fasudil and Apoplexy
| Article | Year |
|---|---|
FDCA Attenuates Neuroinflammation and Brain Injury after Cerebral Ischemic Stroke.
Topics: Animals; Blood-Brain Barrier; Brain Injuries; Brain Ischemia; Humans; Infarction, Middle Cerebral Ar | 2023 |
Combination of constraint-induced movement therapy with fasudil amplifies neurogenesis after focal cerebral ischemia/reperfusion in rats.
Topics: Animals; Brain Ischemia; Bromodeoxyuridine; Cerebral Infarction; Neurogenesis; Nogo Proteins; Rats; | 2022 |
Treatment with low dose fasudil for acute ischemic stroke in chronic hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cerebrovascular Circulation; Chronic Disease | 2017 |
Rho-kinase inhibition improves ischemic perfusion deficit in hyperlipidemic mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain Ischemia; Cerebrovascular Circulation; | 2014 |
Combination of early constraint-induced movement therapy and fasudil enhances motor recovery after ischemic stroke in rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Analysis of Variance; Animals; Brain Infarction; Brai | 2016 |
Neuroprotection against cerebral ischemia/reperfusion injury by intravenous administration of liposomal fasudil.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Intravenous; Animals; Brain; Brain Is | 2016 |
Increased leukocyte ROCK activity in patients after acute ischemic stroke.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Blotting, Western; Brain Ischemia; Enzyme Inhib | 2009 |
Amelioration of endothelial damage/dysfunction is a possible mechanism for the neuroprotective effects of Rho-kinase inhibitors against ischemic brain damage.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain; Brain Ischemia; Capillary Permeabilit | 2010 |
Simvastatin improves clinical scores in a rabbit multiple infarct ischemic stroke model: synergism with a ROCK inhibitor but not the thrombolytic tissue plasminogen activator.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Anticholesteremic Agents; Brain Infarction; | 2010 |
A Rho kinase (ROCK) inhibitor, fasudil, prevents matrix metalloproteinase-9-related hemorrhagic transformation in mice treated with tissue plasminogen activator.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blotting, Western; Cells, Cultured; Cerebral | 2012 |
Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Analysis of Variance; Animals; Antihypertensi | 2005 |
Vasodilator effects of fasudil, a Rho-kinase inhibitor, on retinal arterioles in stroke-prone spontaneously hypertensive rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Analysis of Variance; Animals; Blood Pressure; Dose-R | 2007 |
A new model of cerebral microthrombosis in rats and the neuroprotective effect of a Rho-kinase inhibitor.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain Infarction; Carotid Artery, Internal; | 2000 |